Denali Therapeutics
DNLI
200 hedge funds and large institutions have $2.84B invested in Denali Therapeutics in 2022 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 78 increasing their positions, 56 reducing their positions, and 19 closing their positions.
503% more call options, than puts
Call options by funds: $3.05M | Put options by funds: $506K
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
39% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 56
6% more funds holding
Funds holding: 188 → 200 (+12)
4% more capital invested
Capital invested by funds: $2.73B → $2.84B (+$109M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.45% less ownership
Funds ownership: 75.39% → 74.94% (-0.45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.4M |
| 3 |
Goldman Sachs
New York
|
+$10M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$9.04M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$8.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$48.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36.8M |
| 3 |
CC
Casdin Capital
New York
|
-$16.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.6M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$11.3M |
DNLI Hedge Fund Activity: Q3 2022 in Review
200 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q3 2022, worth a combined $2.84B — up 4% from $2.73B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new DNLI positions and 19 closed out — a net gain of 13 holders — while 78 added to existing stakes and 56 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $20.6M. The largest seller was Arch Venture Management, cutting an estimated $48.8M.
- 200 institutional investors held Denali Therapeutics (DNLI) as of Q3 2022, up from 188 in Q2 2022.
- Funds reported $2.84B of Denali Therapeutics stock for Q3 2022, up 4% quarter-over-quarter.
- 32 funds opened new Denali Therapeutics positions in Q3 2022 and 19 closed out, a net change of +13 holders.
- The largest Denali Therapeutics buyer in Q3 2022 was Point72 Asset Management, an estimated $20.6M added.
- The largest Denali Therapeutics seller in Q3 2022 was Arch Venture Management, an estimated $48.8M sold.
Based on aggregated 13F filings for Q3 2022.